1. Epidemiology of Diabetes
Question: Based on current evidence, what is the estimated number of
Americans with diabetes?
a) 12 million
b) 20.4 million
c) 23.6 million
d) 30.3 million
Answer: d) 30.3 million
Rationale: The document states that in 2017, 9.4% of the U.S. population
had diabetes, translating to 30.3 million people. Understanding
epidemiological data is crucial for public health initiatives and treatment
planning.
2. Mechanism of Action of Metformin
Question: All of the following are actions of Metformin therapy, except:
a) Decreases hepatic glucose production
b) Increases beta cell production of insulin
c) Decreases intestinal absorption of glucose
d) Increases peripheral glucose uptake and utilization
Answer: b) Increases beta cell production of insulin
Rationale: Metformin primarily works by decreasing hepatic glucose
production, increasing insulin sensitivity, and reducing glucose absorption
in the intestine. It does not stimulate beta cells to produce insulin, unlike
sulfonylureas.
3. Insulin Therapy
Question: The onset of action for regular insulin is:
a) 10-15 minutes
b) 15-30 minutes
c) 60-90 minutes
d) 3-4 hours
Answer: b) 15-30 minutes
Rationale: Regular insulin has an onset of action of 15-30 minutes, peaks
at 2-4 hours, and lasts 6-12 hours. This knowledge is essential for
appropriate meal planning and insulin administration.
,4. Sulfonylurea Side Effects
Question: Potential side effects of sulfonylureas include all of the following
except:
a) Weight gain
b) Liver failure
c) Hypoglycemia
d) Gastrointestinal disturbances
Answer: b) Liver failure
Rationale: Sulfonylureas primarily cause hypoglycemia and weight gain
due to increased insulin secretion. They can also cause mild gastrointestinal
issues but are not directly linked to liver failure.
5. Gestational Diabetes Management
Question: Which of the following statements about gestational diabetes
management is correct?
a) Insulin is the first-line treatment
b) Metformin is the preferred drug due to its safety profile
c) Blood sugar targets are more lenient than in non-pregnant diabetics
d) No pharmacological treatment is needed if blood sugars are slightly
elevated
Answer: a) Insulin is the first-line treatment
Rationale: The document states that lifestyle modifications (LSM) are first-
line, but if blood glucose cannot be controlled, insulin is the preferred
pharmacologic agent, as Metformin crosses the placenta.
6. GLP-1 Agonists and Cardiovascular Benefits
Question: Which of the following GLP-1 receptor agonists has been shown
to reduce cardiovascular risk?
a) Exenatide
b) Liraglutide
c) Albiglutide
d) Lixisenatide
Answer: b) Liraglutide
Rationale: The document highlights that Liraglutide has demonstrated a
13% reduction in cardiovascular events and a 20% reduction in all-cause
, mortality, making it a preferred agent in patients with diabetes and
cardiovascular disease.
Case-Based Questions
1. Patient-Centered Diabetes Management
Case: You are seeing a 55-year-old patient with Type 2 Diabetes Mellitus
(T2DM) and hypertension. His HbA1c is 8.5%, and he has a history of
cardiovascular disease (CVD). Which of the following would be the most
appropriate initial treatment option?
a) Sulfonylurea
b) Metformin + GLP-1 receptor agonist
c) Metformin + Thiazolidinedione
d) Insulin glargine
Answer: b) Metformin + GLP-1 receptor agonist
Rationale: The document states that drug selection should be based on
comorbidities. In a patient with T2DM and CVD, a GLP-1 receptor agonist
(such as Liraglutide) is preferred due to its cardiovascular benefits.
Metformin remains the first-line treatment unless contraindicated.
2. Managing Hypoglycemia
Case: A 65-year-old male with Type 2 Diabetes is on a sulfonylurea and
metformin. He reports frequent episodes of dizziness and sweating,
especially before meals. His HbA1c is 6.4%. What is the best course of
action?
a) Discontinue metformin
b) Reduce sulfonylurea dose or discontinue it
c) Add basal insulin
d) Prescribe a GLP-1 receptor agonist
Answer: b) Reduce sulfonylurea dose or discontinue it
Rationale: Sulfonylureas can cause hypoglycemia, particularly in elderly
patients. Since the HbA1c is already well-controlled (6.4%), reducing or
discontinuing the sulfonylurea would help prevent hypoglycemic episodes.
3. Selecting Insulin for a Newly Diagnosed Type 1 Diabetic
Question: Based on current evidence, what is the estimated number of
Americans with diabetes?
a) 12 million
b) 20.4 million
c) 23.6 million
d) 30.3 million
Answer: d) 30.3 million
Rationale: The document states that in 2017, 9.4% of the U.S. population
had diabetes, translating to 30.3 million people. Understanding
epidemiological data is crucial for public health initiatives and treatment
planning.
2. Mechanism of Action of Metformin
Question: All of the following are actions of Metformin therapy, except:
a) Decreases hepatic glucose production
b) Increases beta cell production of insulin
c) Decreases intestinal absorption of glucose
d) Increases peripheral glucose uptake and utilization
Answer: b) Increases beta cell production of insulin
Rationale: Metformin primarily works by decreasing hepatic glucose
production, increasing insulin sensitivity, and reducing glucose absorption
in the intestine. It does not stimulate beta cells to produce insulin, unlike
sulfonylureas.
3. Insulin Therapy
Question: The onset of action for regular insulin is:
a) 10-15 minutes
b) 15-30 minutes
c) 60-90 minutes
d) 3-4 hours
Answer: b) 15-30 minutes
Rationale: Regular insulin has an onset of action of 15-30 minutes, peaks
at 2-4 hours, and lasts 6-12 hours. This knowledge is essential for
appropriate meal planning and insulin administration.
,4. Sulfonylurea Side Effects
Question: Potential side effects of sulfonylureas include all of the following
except:
a) Weight gain
b) Liver failure
c) Hypoglycemia
d) Gastrointestinal disturbances
Answer: b) Liver failure
Rationale: Sulfonylureas primarily cause hypoglycemia and weight gain
due to increased insulin secretion. They can also cause mild gastrointestinal
issues but are not directly linked to liver failure.
5. Gestational Diabetes Management
Question: Which of the following statements about gestational diabetes
management is correct?
a) Insulin is the first-line treatment
b) Metformin is the preferred drug due to its safety profile
c) Blood sugar targets are more lenient than in non-pregnant diabetics
d) No pharmacological treatment is needed if blood sugars are slightly
elevated
Answer: a) Insulin is the first-line treatment
Rationale: The document states that lifestyle modifications (LSM) are first-
line, but if blood glucose cannot be controlled, insulin is the preferred
pharmacologic agent, as Metformin crosses the placenta.
6. GLP-1 Agonists and Cardiovascular Benefits
Question: Which of the following GLP-1 receptor agonists has been shown
to reduce cardiovascular risk?
a) Exenatide
b) Liraglutide
c) Albiglutide
d) Lixisenatide
Answer: b) Liraglutide
Rationale: The document highlights that Liraglutide has demonstrated a
13% reduction in cardiovascular events and a 20% reduction in all-cause
, mortality, making it a preferred agent in patients with diabetes and
cardiovascular disease.
Case-Based Questions
1. Patient-Centered Diabetes Management
Case: You are seeing a 55-year-old patient with Type 2 Diabetes Mellitus
(T2DM) and hypertension. His HbA1c is 8.5%, and he has a history of
cardiovascular disease (CVD). Which of the following would be the most
appropriate initial treatment option?
a) Sulfonylurea
b) Metformin + GLP-1 receptor agonist
c) Metformin + Thiazolidinedione
d) Insulin glargine
Answer: b) Metformin + GLP-1 receptor agonist
Rationale: The document states that drug selection should be based on
comorbidities. In a patient with T2DM and CVD, a GLP-1 receptor agonist
(such as Liraglutide) is preferred due to its cardiovascular benefits.
Metformin remains the first-line treatment unless contraindicated.
2. Managing Hypoglycemia
Case: A 65-year-old male with Type 2 Diabetes is on a sulfonylurea and
metformin. He reports frequent episodes of dizziness and sweating,
especially before meals. His HbA1c is 6.4%. What is the best course of
action?
a) Discontinue metformin
b) Reduce sulfonylurea dose or discontinue it
c) Add basal insulin
d) Prescribe a GLP-1 receptor agonist
Answer: b) Reduce sulfonylurea dose or discontinue it
Rationale: Sulfonylureas can cause hypoglycemia, particularly in elderly
patients. Since the HbA1c is already well-controlled (6.4%), reducing or
discontinuing the sulfonylurea would help prevent hypoglycemic episodes.
3. Selecting Insulin for a Newly Diagnosed Type 1 Diabetic
